Diagnostic testing in hepatitis C virus infection: Viral kinetics and genomics

Seminars in Liver Disease

Volumn 23, Issue SUPPL. 1, 2003, Pages 3-11

  Pawlotsky, Jean Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

HCV resistance; HCV RNA quantification; Hepatitis C virus; Viral genomics; Viral kinetics

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DECISION MAKING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; TREATMENT FAILURE; VIRUS CELL INTERACTION; VIRUS DIAGNOSIS; VIRUS GENE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS TRANSMISSION;

ALGORITHMS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL;

EID: 0042820370     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
3. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36 (Suppl 1):3
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
5. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999;31(Suppl 1):54-60
6. Soler M, Pellerin M, Malnou CE, et al. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology 2002;298: 160-173
7. Ross RS, Viazov SO, Holtzer CD, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000;38:3581-3584
8. Ansaldi F, Torre F, Bruzzone BM, et al. Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. J Med Virol 2001;63:17-21
9. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102
10. Stuyver L, Wyseur A, van Arnhem W, et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995; 38:137-157
11. Stuyver L, Wyseur A, van Arnhem W, et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-2266
12. Pawlotsky JM, Prescott L, Simmonds P, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997;35: 1734-1739
13. Leruez-Ville M, Nguyen QT, Cohen P, et al. Large-scale analysis of hepatitis C virus serological typing assay: effectiveness and limits. J Med Virol 1998;55:18-23
14. Prescott LE, Berger A, Pawlotsky JM, et al. Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays. J Med Virol 1997;53:237-244
15. Sandres K, Dubois M, Pasquier C, et al. Determination of HCV genotype using two antibody assays and genome typing. Eur J Clin Microbiol Infect Dis 2001;20:666-669
16. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107
17. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002; 36:211-218
18. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36:S65-S73
19. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26:B303-B320
20. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-2099
21. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003;37:60-64
22. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-1447
23. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231
24. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35
25. Neumann AU, Buti M, Lurie Y, et al. The second phase HCV decline slope is the best predictor of sustained viral response during treatment of chronic HCV genotype 1 patients with peginterferon alfa-2b and ribavirin. Hepatology 2002;36:357A
26. Neumann AU, Zeuzem S, Ferrari C, et al. Ditto-HCV early viral kinetics report: novel decline patterns in genotype 1 but not genotypes 2 and 3 patients treated with peg-interferon alfa-2a and ribavirin. J Hepatol 2002;36(Suppl 1):121
27. , Pawlotsky JM, Neumann AU, Dahari H, et al. Hepatitis C virus dynamics during induction therapy with interferon alpha and/or ribavirin. Hepatology 2000;32:223A
28. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-1568
29. Urdea MS, Horn T, Fultz TJ, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991;24:197-200
30. Saiki RK, Bugawan TL, Horn GT, et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986;324:163-166
31. Compton J. Nucleic acid sequence-based amplification. Nature 1991;350:91-92
32. Higuchi R, Fockler C, Dollinger G, et al. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 1993;11:1026-1030
33. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res 1996;6:986-994
34. Chen RW, Piiparinen H, Seppanen M, et al. Real-time PCR for detection and quantitation of hepatitis B virus DNA. J Med Virol 2001;65:250-256
35. Andrus A, Cox S, Beavers S, et al. High-throughput synthesis of functionalized oligonucleotides. Nucleic Acids Syrnp Ser 1997:317-318
36. Parks SB, Popovich BW, Press RD. Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes. Am J Clin Pathol 2001;115:439-447
37. White PA, Pan Y, Freeman AJ, et al. Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR. J Clin Microbiol 2002;40:4346-4348
38. Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M, et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods 2001;95:111-119
39. Yang JH, Lai JP, Douglas SD, et al. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 2002;102:119-128
40. Takeuchi T, Katsume A, Tanaka T, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999;116:636-642
41. Martell M, Gomez J, Esteban JI, et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999;37:327-332
42. Enomoto M, Nishiguchi S, Shiomi S, et al. Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. J Gastroenterol Hepatol 2001;16:904-909
43. Lee CL, Schlag P, Antony A, et al. Evaluation of TaqMan HCV ASR. Hepatology 2002;36:346A
44. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999;76:149-158
45. Saldanha J, Heath A, Lelie N, et al. Calibration of HCV working reagents for NAT assays against the HCV international standard. Vox Sang 2000;78:217-224
46. Pawlotsky JM, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32:654-659
47. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999
48. Duvoux C, Pawlotsky JM, Bastie A, et al. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 1999;31:593-597
49. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207
50. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:S201-S209
51. Pawlotsky JM, Martinot-Peignoux M, Poveda JD, et al. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. J Virol Methods 1999;79:227-235
52. Yu ML, Chuang WL, Dai CY, et al. Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV version 2.0 test. J Clin Microbiol 2000;38:2933-2939
53. Gerken G, Rothaar T, Rumi MG, et al. Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000; 38:2210-2214
54. Martinot-Peignoux M, Boyer N, Le Breton V, et al. A new step toward standardization of serum hepatitis C virus RNA quantification in patients with chronic hepatitis C. Hepatology 2000;31:726-729
55. Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-4179
56. Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology 1997;26:1-4
57. Pradat P, Chossegros P, Bailly F, et al. Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat 2000;7:203-210
58. Reichard O, Norkrans G, Fryden A, et al. Comparison of 3 quantitative HCV RNA assays. Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998;30:441-446
59. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991;180:842-848
60. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-3229
61. Pawlotsky JM, Germanidis G, Neumann AU, et al. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998; 72:2795-2805
62. Pawlotsky JM, Germanidis G, Frainais PO, et al. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999;73:6490-6499
63. Gretch DR, Polyak SJ, Wilson JJ, et al. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996;70: 7622-7631
64. Polyak SJ, McArdle S, Liu SL, et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998;72:4288-4296
65. Smith DB, McAllister J, Casino C, et al. Virus "quasispecies": making a mountain out of a molehill? J Gen Virol 1997;78: 1511-1519
66. Pawlotsky JM, Gretch DR. Molecular tools for the treatment of hepatitis C. Antivir Ther 1998;3:45-55
67. Pawlotsky JM. Antiviral treatment failure in chronic hepatitis C. Antiviral Res 2003;(in press)
68. Penin F, Dubuisson J, Rey F, et al. Structural biology of hepatitis C virus. Hepatology 2003;(in press)
69. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002;36:S245-S252
70. Benhamou Y, Hinrichsen H, Sentjens R, et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over two days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 2002;36:304A
71. Hinrichsen H, Benhamou Y, Reiser M, et al. First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 2002;36:379A
72. De Francesco R, Rice CM. New therapies on the horizon for hepatitis C: are we close? Clin Liver Dis 2003;7:211-242
73. Soler M, Penin F, Ray S, et al. Hepatitis C virus NS3 serine protease variability and evolution are strongly constrained by the need for structural and functional conservation. J Hepatol 2002;36(Suppl 1):5
74. Pietschmann T, Bartenschlager R. Tissue culture and animal models for hepatitis C virus. Clin Liver Dis 2003;7:23-43